借本次访华契机，多家德国企业计划进一步放开与中国科技企业的合作，已有具体合作计划或明确合作 意向，这将直接利好中国相关产业链。 （文章来源：21世纪经济报道） 2月25日至26日，德国总理默茨对中国进行正式访问，这是他就任以来首次访华。此次约30位来自汽 车、化工、生物制药、机械制造、循环经济等德国优势领域的头部企业高管随同默茨总理访华。 2025年，德国对华投资达到四年来的最高水平。最新企业信心调查报告也显示，93%的在华德企仍计划 维持或扩大合作。 ...

2026.02.26 本文字数：1121，阅读时长大约2分钟 作者 |第一财经 林志吟 封图｜第一财经记者任玉明摄 2月26日下午临近收盘时，百济神州（ONC.NS、06160.HK、688235.SH）港股股价突然暴跌，最后以大 跌9.16%收盘。伴随着股价大跌，公司港股市场的市值也跌破3000亿港元，最后报2995亿港元，由此引 发市场对公司即将发布的业绩快报的担忧。 2月26日晚间，百济神州发布的2025年度业绩快报显示，2025年，公司营业总收入达382.05亿元，同比 增长40.4%。得益于产品收入增长和费用管理推动的经营效率提升，归属于母公司所有者的净利润达 14.22亿元，首次实现全年盈利。 不过，百济神州收入第一高产品，BTK抑制剂百悦泽（泽布替尼）收入虽然再创新高，2025年全球销售 额达280.67亿元，但同比增速为48.8%，较2023年、2024年的翻倍增长有所放缓。 百悦泽优势主要在血液瘤领域，销售放缓背后，其实跟美国市场表现有关，虽然美国仍是这款药物最大 的商业化市场，贡献的销售额达到202.06亿元，同比增长45.5%，但这样的销售增速低于2024年107.5% 的增速。 作为百 ...

Financial Data and Key Metrics Changes - The company reported record Q4 total revenue of $92.9 million, representing a 23% increase year-over-year, exceeding guidance for the quarter [4][15] - Full-year total revenue increased to $276.3 million, surpassing the high end of guidance [15] - Gross margin for Q4 was nearly 80%, with adjusted EBITDA margin at 40%, marking the highest quarterly margins to date [4][15] - Full-year GAAP net income grew nearly 60% to $16.5 million, with a gross margin of 74%, an increase of nearly 200 basis points compared to the prior year [16] Business Line Data and Key Metrics Changes - MACI generated record Q4 revenue of $84.1 million, reflecting a 23% increase year-over-year and 51% sequential growth from Q3 [15] - Full-year MACI revenue increased by 21% to $239.5 million [15] - Burn care Q4 revenue was $8.8 million, exceeding guidance, with full-year burn care revenue at $36.8 million [15] Market Data and Key Metrics Changes - MACI's performance showed strong growth with over 20,000 patients treated since launch, achieving a compound annual revenue growth of 24% over the past nine years [6][7] - The company noted that MACI's pricing and reimbursement profile remained strong, with prior authorization approval rates over 95% for commercial patients in 2025 [8] Company Strategy and Development Direction - The company aims to capitalize on a larger MACI sales force to increase reach and penetration within the existing surgeon base [8][9] - Strategic initiatives include enhancing commercial analytics and standardizing best practices across the sales team to drive deeper penetration [9] - The company plans to leverage MACI Arthro to drive growth in smaller cartilage defects, which represent a significant segment of MACI's addressable market [10] - The initiation of the phase III MACI Ankle MASCOT clinical study represents a substantial growth opportunity with an estimated addressable market of over $1 billion [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with strong momentum, expecting total company revenue of approximately $316-$326 million [17][18] - For MACI, revenue guidance is set at approximately $280-$286 million for the full year, reflecting continued growth trends [18] - The company anticipates a similar quarterly mix of MACI revenue as last year, with expectations for continued strong performance in Q1 [19] Other Important Information - The company ended the year with approximately $200 million in cash and investments, with no debt [4][16] - Management highlighted the importance of the BARDA award for NexoBrid, which could provide additional revenue opportunities [65][86] Q&A Session Summary Question: Can you discuss the balance of price versus volume for MACI? - Management indicated that both price and volume are key growth drivers, with recent performance being volume-driven, although pricing remains an important factor [24][26] Question: How does new doctor growth compare to existing customer dynamics? - Management noted that about two-thirds of trained surgeons are existing MACI users, with the remaining one-third being new adopters, and emphasized the positive growth rates among trained surgeons [27][28] Question: Can you clarify the guidance for MACI growth in 2026? - Management explained that the guidance reflects a prudent approach, with expectations for continued growth in MACI, while not baking in any significant inflection in trends [34][36] Question: What are the expectations for the sales force expansion? - Management expressed excitement about the sales force expansion, which is expected to enhance reach and performance, with productivity returning to previous levels quickly [46][47] Question: What is the outlook for NexoBrid and its adoption? - Management confirmed ongoing progress with NexoBrid, noting that they are seeing reactivation of dormant accounts and optimistic about future adoption [64][65]

Financial Data and Key Metrics Changes - The company reported record fourth quarter total revenue of $92.9 million, representing a 23% increase year-over-year, exceeding guidance for the quarter [4][15] - Full year total revenue increased to $276.3 million, above the high end of guidance [15] - Gross margin for the fourth quarter was nearly 80%, with adjusted EBITDA margin at 40%, marking the highest quarterly margins to date [4][17] - Full year GAAP net income grew nearly 60% to $16.5 million, significantly outpacing revenue growth [18] Business Line Data and Key Metrics Changes - MACI generated record fourth quarter revenue of $84.1 million, a 23% increase year-over-year and 51% sequential growth from the third quarter [15][16] - Full year MACI revenue increased 21% to $239.5 million [15] - Burn care revenue for the fourth quarter was $8.8 million, exceeding guidance, with full year burn care revenue at $36.8 million [16][18] Market Data and Key Metrics Changes - MACI's leadership in the cartilage repair market has strengthened, with over 20,000 patients treated since its U.S. launch in 2017 [6] - The company achieved a prior authorization approval rate of over 95% for commercial patients in 2025, indicating strong market acceptance [7] Company Strategy and Development Direction - The company aims to capitalize on a larger MACI sales force to increase reach and penetration among existing surgeons [7][9] - Strategic initiatives include enhancing commercial analytics and standardizing best practices to drive deeper penetration within the surgeon user base [9] - The company initiated the phase 3 MACI Ankle MASCOT clinical study, targeting a market opportunity exceeding $1 billion [12] - Plans for U.K. expansion include submitting a marketing authorization application in mid-2026, with a potential launch in 2027 [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with strong momentum, expecting total company revenue of approximately $316 million to $326 million [19][20] - MACI revenue guidance for 2026 is projected at $280 million to $286 million, reflecting continued growth trends [20] - The company anticipates a similar quarterly revenue mix for MACI as in the previous year, with expectations for sustained growth [20] Other Important Information - The company ended the year with approximately $200 million in cash and investments and no debt, enhancing its financial profile [4][19] - Operating cash flow for the full year was $52 million, indicating a positive cash generation trend [19] Q&A Session Summary Question: How do you think about the mix of price versus volume for MACI? - Management indicated that both price and volume are key growth drivers, with a significant improvement in MACI performance being volume-driven in the second half of the year [29] Question: Can you reflect on new doctor growth and existing sales dynamics? - Approximately two-thirds of trained surgeons are existing MACI users, with the remaining one-third being new or previously untrained surgeons [32] Question: Why is the 2026 MACI growth guidance slightly below previous expectations? - Management stated that the guidance reflects a prudent approach, with no material changes in expectations, and is consistent with prior commentary [38] Question: What are the expectations for the sales force expansion and free cash flow? - The sales force expansion is expected to enhance reach and productivity, while cash flow is anticipated to improve as the company enters a new phase of cash generation [53] Question: How is the company planning for the U.K. expansion? - The company plans to commercialize MACI in the U.K. independently, leveraging established approval and reimbursement pathways [79]

面对每天上千份上市公司公告该看哪些？重大事项公告动辄几十页几百页重点是啥？公告里 一堆专业术语不知道算利好还是利空？请看智通财经公司新闻部《速读公告》栏目，我们派 驻全国的记者们将于公告当晚为您带来准确、快速、专业的解读。 智通财经2月26日讯（记者 何凡）受首款商业化产品销售市场扩张等因素影响，专注于自免疾病等领域 的智翔金泰-U（688443.SH）2025年总营收同比大幅增长，净亏损同比收窄超30%，但公司距离盈利仍 有不小差距。 今日晚间，智翔金泰发布2025年业绩快报，去年，智翔金泰实现营业总收入约2.31亿元，与2024年同期 相比增长666.65%；实现归母净亏损5.36亿元，亏损同比收窄32.74%；扣非归母净亏损5.79亿元，亏损 同比收窄27.99%。但同时这也意味着，截至2025年末，公司仍未盈利，数据显示，2021年—2025年， 智翔金泰5年时间中净亏损已超30亿元。 报告期末，公司总资产为29.93亿元，较上年同期下降4.87%；归属于母公司的所有者权益为15.84亿 元，较上年同期下降25.49%。 对于营收增长的原因，公司表示主要在于，其一，报告期内公司进一步推动首款商业化产品 ...

（文章来源：证券日报） 证券日报网讯 2月26日，百济神州发布公告称，公司预计2026年中国企业会计准则下营业收入介于436 亿元至450亿元之间，毛利率处于80%区间高位，研发费用、销售及管理费用合计介于333亿元至348亿 元之间，营业收入扣除经调整的经营成本费用后介于98亿元至105亿元之间。 ...

证券日报网讯 2月26日，百济神州发布公告称，公司2025年实现营业总收入382.05亿元，同比增长 40.4%；归属于母公司所有者的净利润14.22亿元，实现扭亏为盈。 （文章来源：证券日报） ...

第四季度产品收入净额为1.271亿美元，2024年同期为1.085亿美元，同比增长17%，按固定汇率(CER)计 算增长 16%;2025年全年产品收入净额为4.572亿美元，2024年同期为3.976亿美元，同比增长15%，按 CER计算同比增长16%。产品收入增长主要是由于鼎优乐和纽再乐的销量增长。 智通财经APP讯，再鼎医药(09688)发布公告，2025年第四季度总收入为1.276亿美元，同比增长 17%;2025年全年总收入为4.602亿美元，同比增长15%。2025年第四季度净亏损为5040.9万美元，同比收 窄38.29%;2025年全年净亏损为约1.755亿美元，同比收窄31.73%。截至2025年12月31日，现金及现金等 价物、短期投资和流动受限制现金总计为7.896亿美元。 2025年第四季度的研发开支为6,160万美元，2024年同期为5,230万美元。2025年全年研发开支为2.209亿 美元，2024年同期为2.345亿美元。第四季度研发开支的增加主要源于临床研究的推进。全年研发开支 下降主要得益于战略资源优化调整带来的人员成本下降。 再鼎医药创始人、董事长兼首席执行官杜莹博士表示 ...

（文章来源：证券日报） 证券日报网讯 2月26日，百奥泰在互动平台回答投资者提问时表示，托珠单抗皮下制剂已完成临床试 验，目前正积极推进申报前各项准备工作。 ...

第四季度产品收入净额为1.271亿美元，2024年同期为1.085亿美元，同比增长17%，按固定汇率(CER)计 算增长16%;2025年全年产品收入净额为4.572亿美元，2024年同期为3.976亿美元，同比增长15%，按 CER计算同比增长16%。产品收入增长主要是由于鼎优乐和纽再乐的销量增长。 再鼎医药总裁兼首席运营官Josh Smiley表示："KarXT是再鼎重要的新增长引擎，近期其被纳入了国家 精神分裂症专家共识，凸显了其创新机制及为精神分裂症患者带来有意义影响的潜力，正不断获得更加 广泛的认可。我们正在通过扩大医院覆盖和支持更长的治疗周期，进一步巩固艾加莫德的市场地位。同 时，我们正积极准备TIVDAK的获批上市—这将进一步强化我们在妇瘤领域的管线布局，以及肿瘤电场 治疗用于胰腺癌的潜在获批。展望2026年及未来，新产品上市、潜在适应证拓展以及全球项目的推进， 将助力我们实现未来多年的增长和财务状况的持续改善。" 公告称，亏损净额减少主要是由于产品收入增长快于运营开支以及汇兑损失转为汇兑收益，但被利息收 益减少所抵销。 再鼎医药(09688)发布公告，2025年第四季度总收入为1.276亿美元 ...